CYSTM1

Across TCGA pan-cancer cohorts, CYSTM1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYSTM1 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CYSTM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CYSTM1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where CYSTM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.874	0.570	.001	23	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	8	view →
LUAD	DFS	Tertile	III,IV	0.967	0.596	.045	3	view →
UCEC	DFS	Median	All	1.000	0.926	.020	2	view →
GBM	OS	Tertile	All	0.248	0.496	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYSTM1–PDAC (DFS)

Open the PDAC breakdown →